Genexine is the famous Corporate Investor, which was founded in 1999. The company was established in Asia in South Korea. The leading representative office of defined Corporate Investor is situated in the Seongnam.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - China. Moreover, a startup needs to be at the age of 1 and less years to get the investment from the fund. Among the most successful fund investment fields, there are Biotechnology, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight I-Mab Biopharma.
The usual cause for the fund is to invest in rounds with 3 partakers. Despite the Genexine, startups are often financed by C-Bridge Capital. The meaningful sponsors for the fund in investment in the same round are Tasly Pharmaceutical, C-Bridge Capital. In the next rounds fund is usually obtained by Tasly Pharmaceutical, Tally Capital, Hony Capital.
The top activity for fund was in 2017. The fund is constantly included in less than 2 investment rounds annually. Deals in the range of more than 100 millions dollars are the general things for fund.
Related Funds
Fund Name | Location |
208 Seed Ventures | Columbia, Missouri, United States |
Adelie | France, Ile-de-France, Paris |
AlphaPrime Ventures | New York, New York, United States |
Campus Party | Community of Madrid, Madrid, Spain |
dlab | New York, New York, United States |
Forecast Communications | Japan, Tokyo |
Hebei Werain Equity Investment Fund Management | China, Hebei, Shijiazhuang |
Hylink Digital | Beijing, Beijing, China |
Kidstone | China, Hongkou District |
Maryland Momentum Fund | Baltimore, Maryland, United States |
Renjing Yatang Cultural Communication | Beijing, Beijing, China |
Square Enix | Japan, Yamanashi, Yamanashi Prefecture |
Supreme Motors | Kent, United States, Washington |
Verint Systems | Melville, New York, United States |
Volt Capital | California, San Francisco, United States |
Weiji Investment | China, Guangdong, Shenzhen |
Wisdom Choice Global Fund | - |
Yidou Investment | China, Guangdong, Shenzhen |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
GI Innovation | $52M | 12 Apr 2021 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
I-Mab Biopharma | $150M | 23 Mar 2017 | Shanghai |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
GI Innovation | $52M | 12 Apr 2021 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
I-Mab Biopharma | $150M | 23 Mar 2017 | Shanghai |